CA 125在卵巢癌化疗反应监测中的应用

CA 125 in the monitoring of response to chemotherapy of ovarian carcinoma.

作者信息

Quaranta M, Lorusso V, Coviello M, Micelli G, Casamassima A

机构信息

Laboratory Service, Oncologic Institute, Bari, Italy.

出版信息

Int J Cancer Suppl. 1988;3:68-70. doi: 10.1002/ijc.2910410814.

DOI:10.1002/ijc.2910410814

PMID:3209302

Abstract

CA 125 serum levels were assessed in 23 patients undergoing chemotherapy for advanced epithelial ovarian carcinoma (EOC). Rising, falling and unchanged levels correlated with disease in 21 out of 23 (95%) cases. Ten out of 11 patients who showed objective response to chemotherapy had a decrease in antigen levels. Two out of 3 patients with stable disease had unchanged values. Progression was always associated with rising levels. CA 125 is a reliable marker for monitoring response to chemotherapy in advanced epithelial ovarian carcinoma.

摘要

对23例晚期上皮性卵巢癌（EOC）患者进行化疗时评估了血清CA 125水平。在23例患者中的21例（95%）中，CA 125水平升高、降低和未改变与疾病情况相关。11例对化疗有客观反应的患者中有10例抗原水平下降。3例病情稳定的患者中有2例数值未改变。病情进展总是与CA 125水平升高相关。CA 125是监测晚期上皮性卵巢癌化疗反应的可靠标志物。